Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The current study seeks to further investigate the impact of up-front systemic therapy in
combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic
adenocarcinoma.